Showing 711-720 of 7324 results for "".
Inside Cosmeceutical Marketing Claims
https://practicaldermatology.com/topics/general-topics/inside-cosmeceutical-marketing-claims/21642/Dermatologists and their patients may wonder what makes a product “dermatologist tested” or “clinically proven.” Here's what you need to know.Update on the Safety and Efficacy of Nicotinamide for Skin Cancer Chemoprevention
https://practicaldermatology.com/topics/skin-cancer-photoprotection/update-on-the-safety-and-efficacy-of-nicotinamide-for-skin-cancer-chemoprevention/57251/Nicotinamide, also known as niacinamide, is a water-soluble vitamin B3 derivative that has long been associated with beneficial impacts on skin cancer risk.The Future of Treatment and Research for Giant Congenital Melanocytic Nevi
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-future-of-treatment-and-research-for-giant-congenital-melanocytic-nevi/57252/Congenital melanocytic nevi (CMN) have long posed a clinical paradox: lesions that are often benign in behavior yet burdened by a measurable risk of melanoma and significant psychosocial impact. Present at birth or emerging in early infancy, CMN vary widely in size, distribution, and long-term impliBiologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.Rediscovering Topical Antifungal Therapy for Onychomycosis
https://practicaldermatology.com/topics/hair-nails/rediscovering-topical-antifungal-therapy-for-onychomycosis/22974/A number of potential topical therapies for onychomycosis have failed clinical investigation. Do we at last have a viable alternative to oral treatment options?Newly Approved Therapies for the Treatment of Plaque Psoriasis in Adults
https://practicaldermatology.com/topics/psoriasis/newly-approved-therapies-for-the-treatment-of-plaque-psoriasis-in-adults/23213/Here’s a closer a look at recently approved agents.Microbiome in Practice: Assessing OTC Options
https://practicaldermatology.com/topics/atopic-dermatitis/microbiome-in-practice-assessing-otc-options/23123/There’s still much to learn, but clinicians already have tools to manipulate the microbiome.Are We Overlooking Skin Cancer in Ethnic Minorities?
https://practicaldermatology.com/issues/supplements/are-we-overlooking-skin-cancer-in-ethnic-minorities/21718/Skin cancers in Hispanic and African American patients may be detected at more advanced stages, leading to poorer prognoses and long-term outcomes compared to non-Hispanic whites.Monitoring Biologic Therapy In Psoriasis: A Primer
https://practicaldermatology.com/topics/psoriasis/monitoring-biologic-therapy-in-psoriasis-a-primer/20931/Treatments are generally safe and well-tolerated, however, prescribers must monitor for risk factors.Maui Derm 2024 and Maui Derm Caribbean: Top Stories, Interviews, and More
https://practicaldermatology.com/conferences/maui-derm-2024/maui-derm-2024-and-maui-derm-caribbean-top-stories-interviews-and-more/24043/The sun was bright, and the science was hot at Maui Derm 2024, held at the Grand Wailea Resort in Maui, Hawaii. From new therapies to innovative techniques to treatments in the pipeline, presenters and attendees were eager to share updates and findings at this popular annual event.